Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors

Eli Hershkovitz, Miriam Marbach, Emili Bosin, Joseph Levy, Charles Roberts, Derek Leroith, Andrew V. Schally, Yoav Sharoni

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Several studies have supported the idea that LH-releasing hormone (LHRH) antagonists have a direct effect on mammary tumor cells. In this study, we have evaluated the potential role of the insulin-like growth factors (IGFs) on the growth of MCF-7 mammary tumor cells and the effect of LHRH analogs on IGF action. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3 times more potent than IGF-II and 30 times more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. IGFs released by MCF-7 cells were measured by specific RIA after acid extraction and chromatography, so as to avoid the interference of IGF-binding proteins. MCF-7 cells secreted IGF-II, but not IGF-I. Estradiol (10-9 mol/L) stimulated IGF-II release; this release preceded the effect of estradiol on cell growth. The LHRH antagonist [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit 6,D-Ala10]LHRH (SB-75, CETRORELIX) inhbited basal, estrogen-induced, and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from MCF-7 cells. This effect preceeded the inhibition of tumor cell growth. We conclude that a LHRH antagonist can inhibit the growth of breast tumors by interfering with the automne action of IGF-II and by directly inhibiting the growth stimulatory effect of IGFs.

Original languageEnglish (US)
Pages (from-to)963-968
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume77
Issue number4
StatePublished - Oct 1993
Externally publishedYes

Fingerprint

Hormone Antagonists
Insulin-Like Growth Factor II
Somatomedins
Gonadotropin-Releasing Hormone
Cells
Breast Neoplasms
Tumors
MCF-7 Cells
Growth
Insulin-Like Growth Factor I
Cell growth
Estradiol
Insulin
Insulin-Like Growth Factor Binding Proteins
IGF Type 1 Receptor
Chromatography
Intercellular Signaling Peptides and Proteins
Estrogens
Acids
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. / Hershkovitz, Eli; Marbach, Miriam; Bosin, Emili; Levy, Joseph; Roberts, Charles; Leroith, Derek; Schally, Andrew V.; Sharoni, Yoav.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 4, 10.1993, p. 963-968.

Research output: Contribution to journalArticle

Hershkovitz, Eli ; Marbach, Miriam ; Bosin, Emili ; Levy, Joseph ; Roberts, Charles ; Leroith, Derek ; Schally, Andrew V. ; Sharoni, Yoav. / Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. In: Journal of Clinical Endocrinology and Metabolism. 1993 ; Vol. 77, No. 4. pp. 963-968.
@article{40819799063749a0a3c1ab446b196e99,
title = "Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors",
abstract = "Several studies have supported the idea that LH-releasing hormone (LHRH) antagonists have a direct effect on mammary tumor cells. In this study, we have evaluated the potential role of the insulin-like growth factors (IGFs) on the growth of MCF-7 mammary tumor cells and the effect of LHRH analogs on IGF action. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3 times more potent than IGF-II and 30 times more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. IGFs released by MCF-7 cells were measured by specific RIA after acid extraction and chromatography, so as to avoid the interference of IGF-binding proteins. MCF-7 cells secreted IGF-II, but not IGF-I. Estradiol (10-9 mol/L) stimulated IGF-II release; this release preceded the effect of estradiol on cell growth. The LHRH antagonist [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit 6,D-Ala10]LHRH (SB-75, CETRORELIX) inhbited basal, estrogen-induced, and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from MCF-7 cells. This effect preceeded the inhibition of tumor cell growth. We conclude that a LHRH antagonist can inhibit the growth of breast tumors by interfering with the automne action of IGF-II and by directly inhibiting the growth stimulatory effect of IGFs.",
author = "Eli Hershkovitz and Miriam Marbach and Emili Bosin and Joseph Levy and Charles Roberts and Derek Leroith and Schally, {Andrew V.} and Yoav Sharoni",
year = "1993",
month = "10",
language = "English (US)",
volume = "77",
pages = "963--968",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors

AU - Hershkovitz, Eli

AU - Marbach, Miriam

AU - Bosin, Emili

AU - Levy, Joseph

AU - Roberts, Charles

AU - Leroith, Derek

AU - Schally, Andrew V.

AU - Sharoni, Yoav

PY - 1993/10

Y1 - 1993/10

N2 - Several studies have supported the idea that LH-releasing hormone (LHRH) antagonists have a direct effect on mammary tumor cells. In this study, we have evaluated the potential role of the insulin-like growth factors (IGFs) on the growth of MCF-7 mammary tumor cells and the effect of LHRH analogs on IGF action. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3 times more potent than IGF-II and 30 times more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. IGFs released by MCF-7 cells were measured by specific RIA after acid extraction and chromatography, so as to avoid the interference of IGF-binding proteins. MCF-7 cells secreted IGF-II, but not IGF-I. Estradiol (10-9 mol/L) stimulated IGF-II release; this release preceded the effect of estradiol on cell growth. The LHRH antagonist [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit 6,D-Ala10]LHRH (SB-75, CETRORELIX) inhbited basal, estrogen-induced, and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from MCF-7 cells. This effect preceeded the inhibition of tumor cell growth. We conclude that a LHRH antagonist can inhibit the growth of breast tumors by interfering with the automne action of IGF-II and by directly inhibiting the growth stimulatory effect of IGFs.

AB - Several studies have supported the idea that LH-releasing hormone (LHRH) antagonists have a direct effect on mammary tumor cells. In this study, we have evaluated the potential role of the insulin-like growth factors (IGFs) on the growth of MCF-7 mammary tumor cells and the effect of LHRH analogs on IGF action. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3 times more potent than IGF-II and 30 times more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. IGFs released by MCF-7 cells were measured by specific RIA after acid extraction and chromatography, so as to avoid the interference of IGF-binding proteins. MCF-7 cells secreted IGF-II, but not IGF-I. Estradiol (10-9 mol/L) stimulated IGF-II release; this release preceded the effect of estradiol on cell growth. The LHRH antagonist [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit 6,D-Ala10]LHRH (SB-75, CETRORELIX) inhbited basal, estrogen-induced, and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from MCF-7 cells. This effect preceeded the inhibition of tumor cell growth. We conclude that a LHRH antagonist can inhibit the growth of breast tumors by interfering with the automne action of IGF-II and by directly inhibiting the growth stimulatory effect of IGFs.

UR - http://www.scopus.com/inward/record.url?scp=0027432715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027432715&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 963

EP - 968

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -